Premium
Therapeutic Bayesian monitoring of sunitinib in two patients with impaired absorption or elimination
Author(s) -
Leenhardt Fanny,
Viala Marie,
Tosi Diego,
SamalinScalzi Emmanuelle,
Evrard Alexandre,
Mbatchi Litaty C.
Publication year - 2021
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.13424
Subject(s) - sunitinib , pharmacokinetics , therapeutic drug monitoring , medicine , adverse effect , bayesian probability , oncology , pharmacology , cancer , statistics , mathematics
What is known and Objective Sunitinib pharmacokinetics can be influenced by the physio‐pathological conditions of individual patients. Therapeutic drug monitoring (TDM) helps to optimize efficacy and reduce the risk of adverse effects. We report on the use of Bayesian analysis to optimize sunitinib blood levels. Case Summary We describe two patients with risk of sunitinib pharmacokinetic variability due to gastrectomy and ongoing haemodialysis, respectively. TDM and Bayesian estimation allowed maintaining their sunitinib pharmacokinetic profiles within the usual limits. What is new and conclusion Our analysis showed that Bayesian analysis can be successfully applied for real‐time TDM to optimize sunitinib blood levels in patients with major comorbidities.